A recent study on the gut and oral microbiome of a cohort of melanoma patients undergoing an anti-PD-1 therapy revealed crucial differences in the diversity and composition of the patients’ gut microbiome of responders vs. non-responders (216). This evidence concerns the gene PDCD1 and melanoma.